

2017

## Health Care Competition Law in the Shadow of State Action: Minimizing MACs

David A. Hyman

William E. Kovacic

Follow this and additional works at: <https://lawcommons.luc.edu/lucj>



Part of the [Law Commons](#)

---

### Recommended Citation

David A. Hyman, & William E. Kovacic, *Health Care Competition Law in the Shadow of State Action: Minimizing MACs*, 48 Loy. U. Chi. L. J. 757 ().

Available at: <https://lawcommons.luc.edu/lucj/vol48/iss3/9>

This Article is brought to you for free and open access by LAW eCommons. It has been accepted for inclusion in Loyola University Chicago Law Journal by an authorized editor of LAW eCommons. For more information, please contact [law-library@luc.edu](mailto:law-library@luc.edu).

# Health Care Competition Law in the Shadow of State Action: Minimizing MACs

David A. Hyman\* & William E. Kovacic\*\*

*How should we go about reconciling competition and consumer protection in health care given the long shadow cast by the state action doctrine? We consider that issue using a case study drawn from an obscure corner of the pharmaceutical reimbursement market to motivate and inform our analysis. We show how the balance between competition and consumer protection is distorted by the political economy of health care regulation—compounded by the extension of the state action doctrine far past its defensible borders. If anything, considerations of political economy argue for much greater skepticism about the utility of regulation—and of the state action doctrine—in the health care space.*

INTRODUCTION .....	758
I. RECONCILING COMPETITION AND CONSUMER PROTECTION IN HEALTH CARE .....	761
II. THE STATE ACTION DOCTRINE .....	763
III. PHARMACEUTICAL MARKETS AND MACS .....	764
A. Pricing and the Life Cycle of Generic Drugs .....	765
B. Pricing and Supply Chain Competition .....	766
C. MACs' Origins .....	767
D. Private Sector Use of MACs .....	768

---

\* Professor of Law, Georgetown University. From 2001 to 2004, he served as Special Counsel at the Federal Trade Commission. In 2015, Hyman was retained by PCMA, the trade association for PBMs, to prepare a white paper on the competitive consequences of attempts by various states to regulate MACs. That initial white paper—along with a subsequent version—provides the basis of our analysis in Part IV. Hyman was also retained by PCMA's outside counsel in 2015 to serve as an expert in litigation involving challenges to attempts by Iowa and Arkansas to regulate MACs.

\*\* Visiting Professor, King's College London, Global Competition Professor of Law and Policy, George Washington University Law School, and Non-Executive Director, United Kingdom Competition and Markets Authority. From 2006 to 2011, he served as a member of the Federal Trade Commission and chaired the agency from March 2008 to March 2009. The views expressed here are the Authors' alone. We appreciate the helpful comments of Dr. Monica Noether, and comments from the audience when this Article was presented at the Loyola University School of Law.

E. <i>The Effect of MACs: A Dose of Theory</i> .....	769
1. Incentivizing Pharmacies to Dispense Generics....	769
2. Increasing Competition Among Generic Manufacturers .....	770
3. Ensuring Pharmacies Are Not Overpaid .....	770
4. Lowering Prescription Drug Spending and the Cost of Prescription Drug Coverage .....	770
5. Enhanced Market Efficiency .....	770
F. <i>Legislative Efforts</i> .....	771
G. <i>Likely Effects of MAC Legislation</i> .....	771
H. <i>How the Empire Struck Back: The Political Economy of     MAC Legislation</i> .....	774
1. Consequential Features of MAC Legislation .....	774
2. Some Empirical Evidence .....	776
a. MAC Usage and Levels .....	776
b. Access to Pharmacy Services .....	778
IV. DISCUSSION .....	779
A. <i>How Representative Are MACs?</i> .....	779
B. <i>Balance This!</i> .....	779
C. <i>Implications of Our Analysis for the State Action         Doctrine</i> .....	780
CONCLUSION.....	781

Attempting to protect competition by focusing solely on private restraints is like trying to stop the flow of water at a fork in a stream by blocking only one of the channels. Unless you block both channels, you are not likely to even slow, much less stop, the flow. Eventually, all the water will flow toward the unblocked channel. The same is true of antitrust enforcement. If you create a system in which private price fixing results in a jail sentence, but accomplishing the same objective through government regulation is always legal, you have not completely addressed the competitive problem. You have simply dictated the form that it will take.<sup>1</sup>

#### INTRODUCTION

George Bernard Shaw famously observed that “all professions are

---

1. Timothy J. Muris, Chairman, Fed. Trade Comm’n, State Intervention/State Action—A U.S. Perspective, Remarks at the Fordham Annual Conference on International Antitrust Law & Policy (Oct. 24, 2003), [http://www.ftc.gov/sites/default/files/documents/public\\_statements/state-intervention/state-action-u.s.perspective/fordham031024.pdf](http://www.ftc.gov/sites/default/files/documents/public_statements/state-intervention/state-action-u.s.perspective/fordham031024.pdf).

conspiracies against the laity.”<sup>2</sup> In health care, the bill of particulars is long and distinguished, and includes overt price fixing, attacks on salaried practice and pre-paid health care, and the systematic marginalization and exclusion of competitors.<sup>3</sup> Indeed, Professors Havighurst and King accurately note that the entire history of medical care in the United States is a story in which “outbreaks of . . . competition were ruthlessly suppressed.”<sup>4</sup> Of course, these campaigns were waged in the name of “medical science, quality of care, and professional prerogative,” rather than the naked self-interest of the medical profession.<sup>5</sup> But regardless of the external branding, the effect was the same: the medical profession was able to set the terms of trade, and exclude or substantially limit the authorized scope of practice for new entrants.<sup>6</sup> Emboldened by these successes, other health care providers used similar tactics to protect their turf and set the terms of trade.

In health care, private individuals and entities were the first movers, but those involved quickly recognized the value of enlisting the government in their conspiracies against the laity. Compared to privately imposed restraints on trade, governmental restraints “are more effective and efficient, and include a built-in cartel enforcement mechanism.”<sup>7</sup> And, as we detail below, governmentally imposed restraints are much harder to attack than private restraints.

The consequences of these dynamics were quite predictable. Over

---

2. GEORGE BERNARD SHAW, *THE DOCTOR’S DILEMMA* act 1 (1909). The play was first staged in 1906.

3. See David A. Hyman, *When and Why Lawyers Are the Problem*, 57 DEPAUL L. REV. 267, 272 (2008) (noting that the medical profession has attempted to “resist the forces of competition,” and that these efforts “neatly coincide with the protection of physicians’ incomes, prerogatives, and control of the means of production”). See generally FED. TRADE COMM’N & DEP’T OF JUSTICE, *IMPROVING HEALTH CARE: A DOSE OF COMPETITION* (2004), <http://www.ftc.gov/reports/healthcare/040723healthcarerpt.pdf> [hereinafter FTC-DOJ, *IMPROVING*] (discussing competition law and health law); FED. TRADE COMM’N, *OVERVIEW OF FTC ANTITRUST ACTIONS IN HEALTH CARE SERVICES AND PRODUCTS*, 3–75 (2013), <http://www.ftc.gov/sites/default/files/attachments/competition-policy-guidance/hcupdate.pdf> (discussing conduct that raises antitrust concerns in the health care industry) [hereinafter FTC, *OVERVIEW*].

4. Clark C. Havighurst & Nancy M. P. King, *Private Credentialing of Health Care Personnel: An Antitrust Perspective—Part Two*, 9 AM. J.L. & MED. 263, 291 (1983).

5. *Id.*

6. *Id.* (concluding that the medical profession “was able to repel most attacks along its borders, to force many of its antagonists into alliances, and to confine other would be invaders to narrow enclaves”).

7. David A. Hyman & Shirley Svorny, *If Professions Are Just “Cartels by Another Name,” What Should We Do About It?*, 163 U. PA. L. REV. ONLINE 101, 121 n.99 (2014), [http://scholarship.law.upenn.edu/penn\\_law\\_review\\_online/vol163/iss1/7](http://scholarship.law.upenn.edu/penn_law_review_online/vol163/iss1/7).

time, the health care marketplace became enmeshed in a complex web of interlocking public and private restraints of trade. Not coincidentally, health care spending and the rate of spending growth spiraled upward.

For these and other reasons, health care became a target-rich environment for antitrust enforcers beginning in the early 1970s.<sup>8</sup> Indeed, several generations of enforcement personnel at the Federal Trade Commission (“FTC”) cut their teeth on merger reviews and cases involving every conceivable participant in the health care sector, including hospitals, doctors, pharmaceutical companies, and pharmacy benefit managers (“PBMs”).<sup>9</sup> As we noted in a recent article:

Since the 1970s, the FTC has devoted considerable effort to health care, beginning with a major case challenging restrictions on advertising in the medical profession, and then going on from there to bring cases involving every aspect of the health care delivery system. In health care, the FTC has batted through its entire rotation of policy tools, including numerous cases, rulemaking, advisory opinions, hearings, and competition advocacy. More than any other program, the health care program has paid the rent for the FTC’s charter as a competition authority.<sup>10</sup>

The Department of Justice (“DOJ”) Antitrust Division and state attorneys general have also been active in this space, albeit on a less continuous basis than the FTC.

The campaign against anticompetitive practices within the health care sector has had its ups and downs, but it is clear that it has had an impact on the frequency and severity of privately imposed anticompetitive restraints.<sup>11</sup> The picture for publicly imposed restraints is considerably murkier, because such restraints are effectively insulated from substantive antitrust scrutiny, as long as they qualify as state action—no matter how overtly anticompetitive they are and no matter how flimsy

---

8. We explore the decision of the Federal Trade Commission (“FTC”) to focus on health care markets in William E. Kovacic & David A. Hyman, *Consume or Invest: What Do/Should Agency Leaders Maximize?*, 91 WASH. L. REV. 295 (2016).

9. See, e.g., WILLIAM BLUMENTHAL, FED. TRADE COMM’N, BACKGROUND MATERIALS: A PRIMER ON THE APPLICATION OF ANTITRUST LAW TO THE PROFESSIONS IN THE UNITED STATES (Sept. 29, 2006), [http://www.ftc.gov/sites/default/files/documents/public\\_statements/primer-application-antitrust-law-professions-united-states/20060929cbablumenthalmaterials\\_0.pdf](http://www.ftc.gov/sites/default/files/documents/public_statements/primer-application-antitrust-law-professions-united-states/20060929cbablumenthalmaterials_0.pdf) (reviewing the FTC’s activity in the health care space); FTC-DOJ, IMPROVING, *supra* note 3 (same); FTC, OVERVIEW, *supra* note 3 (same); John E. Kwoka, Jr., *The Federal Trade Commission and the Professions: A Quarter Century of Accomplishment and Some New Challenges*, 72 ANTITRUST L.J. 997 (2005) (same).

10. Kovacic & Hyman, *supra* note 8, at 313.

11. Plus, in yet another example of demand creating supply, there is now a thriving health care antitrust private bar, along with the requisite American Bar Association section, American Health Lawyers Association practice group, and numerous opportunities to obtain continuing legal education (“CLE”) credits for attending health care antitrust conferences in glamorous locales.

their supposed justification. And, in health care, there is no shortage of overtly anticompetitive restraints, imposed on the basis of flimsy or nonexistent evidence, at the behest of politically connected special interests.

These dynamics complicate the already complex process of reconciling competition and consumer protection in health care—because much of what is styled as consumer protection is, in fact, provider protection. The same dynamics also argue in favor of re-examining the appropriate boundaries of the state action doctrine.

This Article examines these issues using a case study drawn from an obscure corner of the pharmaceutical reimbursement market—maximum allowable cost (“MAC”) schedules. MACs, which are used to reimburse pharmacies for dispensing generic drugs, were pioneered by state Medicaid programs and subsequently adopted by PBMs. But, in the past few years, MACs have become the focal point of heated controversies between PBMs and pharmacies, triggering legislative action in thirty-seven states. Although the dispute is invariably cast in terms of consumer protection (framed in terms of patients’ ability to access to pharmacy services), this Article makes it clear that the issue is really about protecting the providers of pharmacy services from the disruptive forces of competition.

Part II lays out some of the complexities of reconciling competition and consumer protection in health care. Part III reviews the basics of the state action doctrine. Part IV presents our case study of MACs. Part V sketches out some suggestions on how to improve matters—both for MACs and for the larger set of issues for which MACs are a stand-in.

## I. RECONCILING COMPETITION AND CONSUMER PROTECTION IN HEALTH CARE

How should we think about reconciling competition and consumer protection in health care? The preconditions for perfectly competitive markets (including no barriers to entry or exit; fungible goods; and perfect information) are obviously not applicable to health care. And health care combines high stakes, profound asymmetries of information, and deep moral opposition to acknowledging the existence of resource constraints.

Because of the felt necessities created by these dynamics, health care is a field dominated by regulation. The laundry list of regulations includes strict restrictions on entry (i.e., licensure, accreditation, certificates of need or public necessity, and restrictions on scope of practice); specification of minimum terms of trade (i.e., mandated benefits, any willing providers, and voiding of liability waivers); and

aggressive ex post enforcement (i.e., hospital privileges proceedings, state disciplinary action, and medical malpractice litigation). Each and every one of these regulatory initiatives is sold on the basis that they are absolutely necessary consumer protections—and the alternative is an unregulated market that would operate “as a savage war of all against all, red in tooth and claw, populated solely by charlatans and snake oil vendors.”<sup>12</sup>

Most of the health law professoriate is perfectly fine with this extensive list of anticompetitive restraints. Indeed, if anything, the health law professoriate has devoted most of its time to identifying and cataloging new ways to further tame or supplant the market for health care goods and services. In fairness, such attitudes are inextricably linked to the general political commitments of the law professoriate, and are not limited to professors that focus on health law. But, for the sake of argument, assume that there is a constituency that might be open to arguments in favor of striking an actual balance between competition and consumer protection, rather than simply assuming that anything and everything that emerges from the legislative and regulatory process is a-ok. What would that argument look like?

The argument would begin by noting that markets have developed plenty of strategies for signaling and evaluating quality in health care.<sup>13</sup> It would also observe that competition is itself a powerful tool for protecting consumers. Legislators and regulators are poorly informed under the best of circumstances—and health policy is never made under the best of circumstances. Finally, legislators and regulators do not have anywhere near the proper incentives to arrive at optimal policy solutions.<sup>14</sup>

The most entertaining argument for skepticism about the merits and distributional consequences of legislative/regulatory intervention was cuttingly stated by P.J. O’Rourke:

When government does, occasionally, work, it works in an elitist fashion. That is, government is most easily manipulated by people who have money and power already. This is why government benefits usually go to people who don’t need benefits from government. Government may make some environmental improvements, but these will be improvements for rich bird-watchers. And no one in

---

12. Hyman & Svorny, *supra* note 7, at 116.

13. *Id.*

14. *Id.*

government will remember that when poor people go bird-watching they do it at Kentucky Fried Chicken.<sup>15</sup>

Stated differently, in the health care space, governmental action “generally favors the concentrated interests of incumbent providers and hurts, rather than helps, consumers.”<sup>16</sup> Given the unsavory alliance of Bootleggers and Baptists that is seemingly required to trigger regulatory action in the health care space, any protection of consumers is likely to be incidental or accidental at best.<sup>17</sup> Accordingly, absent proof to the contrary, one should not pretend or assume that health care legislation or regulation actually does much of anything to protect consumers—or was ever intended to do so.<sup>18</sup>

With that unpleasant framing clearly established, we now turn to the state action doctrine, which significantly limits the ability of antitrust enforcers to attack publicly imposed restraints on competition.

## II. THE STATE ACTION DOCTRINE

Federalism requires that we decide whether, when, and how states can deviate from the dictates of federal law. In antitrust, the Supreme Court developed and applied the state action doctrine, which gives states broad discretion to override the commands of federal law.<sup>19</sup> States may enact legislation that contradicts the federal antitrust laws and immunizes private actors from antitrust challenge, so long as the state satisfies two

---

15. P.J. O’ROURKE, *ALL THE TROUBLE IN THE WORLD: THE LIGHTER SIDE OF OVERPOPULATION, FAMINE, ECOLOGICAL DISASTER, ETHNIC HATRED, PLAGUE, AND POVERTY* 199 (1994).

16. David A. Hyman, *Getting the Haves to Come Out Behind: Fixing the Distributive Injustices of American Health Care*, 69 *LAW & CONTEMP. PROBS.* 265, 271 (2006) [hereinafter Hyman, *Getting the Haves*]; David A. Hyman, *Regulating Managed Care: What’s Wrong with a Patient Bill of Rights*, 73 *S. CAL. L. REV.* 221, 271 (2000).

17. Bruce Yandle, *Bootleggers and Baptists in Retrospect*, 22 *REG.* 5, 5 (1999), <https://object.cato.org/sites/cato.org/files/serials/files/regulation/1999/10/bootleggers.pdf> (“[D]urable social regulation evolves when it is demanded by both of two distinctly different groups. ‘Baptists’ point to the moral high ground and give vital and vocal endorsement of laudable public benefits promised by a desired regulation. . . . ‘Bootleggers’ . . . who expect to profit from the very regulatory restrictions desired by Baptists, grease the political machinery with some of the expected proceeds.”).

18. Hyman, *Getting the Haves*, *supra* note 16, at 279 (“[T]o date, provider capture of state and federal legislators and regulators is the rule, and the results have not been pretty. Indeed, the status quo . . . is the direct result of regulatory and legislative oversight, with its known susceptibility to symbolic blackmail, ‘motherhood and apple pie’ initiatives, and other forms of government failure.”).

19. The doctrine originated in *Parker v. Brown*, which rejected a claim that a state-approved scheme to prorate raisin production in California violated the Sherman Act’s ban on monopolization and conspiracies to monopolize. 317 U.S. 341, 368 (1943).



conditions:<sup>20</sup> (1) the state must *clearly articulate* its purpose to suppress rivalry;<sup>21</sup> and (2) the state must *actively supervise* implementation of the anticompetitive regime.<sup>22</sup>

These requirements have tripped up some of the clumsier attempts to use the power of the state to restrict competition.<sup>23</sup> But, for those who are able to follow (fairly simple) directions, the path to a government-enforced cartel is well marked. Unsurprisingly, health care providers have taken full advantage of the invitation to clothe their anticompetitive behavior in the protective garb provided by the state action doctrine. Worse still, courts have shown that they are quite willing to accept even far-fetched invocations of the state action doctrine—although there has been a welcome trend in recent years toward a more restrictive application of the doctrine.<sup>24</sup>

We now turn to our case study, drawn from the depths of the pharmaceutical market.

### III. PHARMACEUTICAL MARKETS AND MACS

Pharmaceuticals come in two varieties: branded and generic. Branded drugs capture most of the media attention and are responsible for a heavily disproportionate share of drug spending—but generic prescriptions account for more than 85 percent of filled prescriptions.<sup>25</sup> Generic drugs are significantly cheaper than branded drugs, but, in recent years, generic drug prices have trended upward—sometimes sharply.<sup>26</sup>

---

20. *Cal. Retail Liquor Dealers Ass'n v. Midcal Aluminum, Inc.*, 445 U.S. 97, 103–04 (1980).

21. *FTC v. Phoebe Putney Health Sys., Inc.*, 133 S. Ct. 1003, 1006 (2013).

22. *N.C. State Bd. of Dental Exam'rs v. FTC*, 135 S. Ct. 1101, 1110 (2015).

23. See *South Carolina State Board of Dentistry*, FED. TRADE COMMISSION, <https://www.ftc.gov/enforcement/cases-proceedings/0210128/south-carolina-state-board-dentistry-matter> (last updated Sept. 11, 2007) (discussing the settlement of a case charging the South Carolina State Board of Dentistry with unlawfully restraining competition by enacting a rule requiring a dentist to examine every child before a dental hygienist could provide preventative dental care in schools, even though that rule was directly contrary to state law).

24. Compare FED. TRADE COMM'N, REPORT OF THE FTC STATE ACTION TASK FORCE 1 (2003), [https://www.ftc.gov/sites/default/files/documents/reports/report-state-action-task-force-recommendations-clarify-and-reaffirm-original-purposes-state-action/stateactionreport\\_0.pdf](https://www.ftc.gov/sites/default/files/documents/reports/report-state-action-task-force-recommendations-clarify-and-reaffirm-original-purposes-state-action/stateactionreport_0.pdf), with *Phoebe Putney Health Sys.*, 133 S. Ct. at 1005 (holding that the hospital authority was not entitled to state action immunity because the State did not clearly articulate or affirm an express policy).

25. Aria A. Razmaria, *Generic Drugs*, 315 JAMA 2746, 2746 (2016).

26. Victoria Colliver, *Prices Soar for Some Generic Drugs*, S.F. CHRON. (Jan. 1, 2014, 12:13 PM), <http://www.sfgate.com/health/article/Prices-soar-for-some-generic-drugs-5105538.php>; Dennis Thompson, *U.S. Prices Soaring for Some Generic Drugs, Experts Say*, U.S. NEWS (Nov. 12, 2014, 5:00 PM), <http://health.usnews.com/health-news/articles/2014/11/12/us-prices-soaring-for-some-generic-drugs-experts-say>.

Like any other product, generic drug pricing is affected by both supply-side and demand-side factors.<sup>27</sup>

How much should pharmacies be paid for dispensing pharmaceuticals—and on what basis? That problem has vexed insurers, PBMs, state Medicaid programs, and health policy experts for decades. In most markets, published prices provide a reasonable starting point (if not the actual benchmark) for gauging the amount that must be paid to acquire a product. But, as we detail below, matters in pharmaceutical markets are considerably more complex—in part because of the product life cycle of generic drugs, and in other part because of competition within the pharmaceutical supply chain. As such, using published prices virtually ensures that pharmacies will be overpaid—sometimes substantially so—for dispensing drugs. Considerable evidence indicates that payors have been overpaying for prescription drugs (both branded and generic) for decades. We focus in this Article on generic drugs. We begin with a brief description of the life cycle of generics, and of the nature of competition within the pharmaceutical supply chain.

#### *A. Pricing and the Life Cycle of Generic Drugs*

A generic pharmaceutical's life cycle typically starts with a 180-day period of marketing exclusivity, which the Food and Drug Administration ("FDA") grants to the first generic that receives approval.<sup>28</sup> During this 180-day period, the first approved generic competes only with the brand name version of the product and any "authorized generics" that the brand manufacturer either makes itself or allows on the market through licensing agreements.

If only one generic is available during the 180-day period, pharmacies can typically acquire the drug for about 20 percent less than the brand "list" price.<sup>29</sup> If "authorized generics" are also available, the competition is greater—so the pharmacy's acquisition cost may be 30 percent less than the brand "list" price.<sup>30</sup> Drug wholesalers also seek to negotiate

---

27. Of late, there has been a significant run-up in the cost of some generic drugs. See Jonathan D. Alpern et al., *High-Cost Generic Drugs—Implications for Patients and Policymakers*, 371 NEW ENG. J. MED. 1859, 1860 (2014) ("Numerous factors may cause price increases for non-patent-protected drugs, including drug shortages, supply disruptions, and consolidations within the generic-drug industry.")

28. To secure this marketing exclusivity, the generic drug company must also file what is known as a "paragraph IV certification." This document indicates that the generic drug company believes any applicable patents are either invalid or will not be infringed.

29. ADAM J. FEIN, DRUG CHANNELS INSTITUTE 2014–15 ECONOMIC REPORT ON RETAIL, MAIL, AND SPECIALTY PHARMACIES 129 (Jan. 2015).

30. *Id.* at 129–30.

discounts, which can be as high as 40–50 percent off the brand “list” price when an authorized generic is available.<sup>31</sup> In a competitive market, these discounts will be passed on to pharmacies. But the “list” price does not typically reflect the impact of these discounts, or it significantly lags the impact of these discounts.

Once the 180-day exclusivity period ends, the market is open to any generic approved by the FDA, and dramatic savings can result if many generics enter the market—as will happen for highly prescribed medications.<sup>32</sup> Again, the “list” price typically does not reflect the impact of these price drops, or it significantly lags the impacts of these price declines.

After one to two years, the market for a particular generic drug typically matures. Some manufacturers may exit the marketplace due to low margins or an eroding market for the drug, or as newer medications in the same class also become available in generic form.<sup>33</sup> Mergers can also reduce the number of manufacturers producing a particular drug. As the number of drug manufacturers declines, prices may increase. Prices may also increase in the event of shortages whether due to manufacturing problems or interruptions in the supply of an active ingredient. Other generic drug manufacturers cannot respond to price increases by entering the market, unless they have FDA approval—and it can be time consuming to obtain that approval. Once again, the “list” price generally does not reflect the impact of this pricing volatility, or it significantly lags the impact of these price changes.

### *B. Pricing and Supply Chain Competition*

Wholesalers routinely offer discounts to pharmacies. The most common discount is for prompt payment, but wholesalers may also provide discounts to pharmacies that purchase a minimum quantity of generic drugs. Alternatively, wholesalers can provide discounts on brand name drugs as long as the pharmacy purchases a minimum volume of generic drugs. Drug wholesalers offer these incentives because they earn a disproportionate share of their profits from generics; in 2014, generics generated 16 percent of wholesaler revenues, but 75 percent of wholesaler profits.<sup>34</sup>

---

31. *Id.* at 130.

32. For example, after the 180-day exclusivity period ended for the first generic version of the Lexapro (a popular antidepressant), the United States Food and Drug Administration (“FDA”) approved eleven additional generics. The additional competition drove the price per 10 mg pill down from \$2.63 to \$0.16 within a month—a 94 percent decrease. *Id.* at 130–31.

33. *Id.* at 131.

34. *Id.* at 113.

To enhance their negotiating leverage, independent pharmacies often form buying groups (i.e., a pharmacy services administrative organization (“PSAO”)) to concentrate their purchases with one or more preferred vendors. In exchange for the PSAO selecting a wholesaler as its preferred vendor, the wholesaler may then agree to provide discounts to the group’s consolidated purchases. Some of these discounts may be paid as a quarterly rebate based on the aggregate volume of generics purchased by the group.<sup>35</sup> None of these discounts or rebates are typically reflected in the “list” prices for generics, and they also may not be reflected in the invoice associated with the drug purchase.

### *C. MACs’ Origins*

When Medicaid was launched it sought to pay providers their actual and justifiable costs—and not one penny more. MACs emerged in the Medicaid program as a tool to do just that: set pharmaceutical spending at the minimum amount necessary to obtain the drug in question. State and federal regulations govern the amount that Medicaid can reimburse for prescription drugs. Before MACs were developed, reimbursement generally involved paying the lesser of the Estimated Acquisition Cost (“EAC”) plus a reasonable dispensing fee, or the providers’ usual and customary charges to the general public. The EAC was typically determined based on published “list” prices, including the Average Wholesale Price (“AWP”).

At one time, the AWP reflected the pharmacy’s acquisition costs, but it quickly became apparent that there was considerable divergence between the AWP and pharmacists’ true acquisition cost, particularly as generic drugs became more prevalent. Once this fact became clear, it was necessary to modify Medicaid’s reimbursement formula to ensure that the amounts paid reflected pharmacists’ actual costs (i.e., the acquisition cost plus the costs associated with dispensing the pharmaceutical).

In 1987, the federal government responded by requiring states to implement an aggregate payment limit for specific drugs.<sup>36</sup> The payment limit (known as a Federal Upper Limit (“FUL”)) was determined mechanically.<sup>37</sup> Pursuant to this payment limit, the dispensing pharmacy

---

35. *Id.* at 112.

36. 42 C.F.R. § 447.301–447.371.

37. The Patient Protection and Affordable Care Act modified the formula for calculating a payment limit. The federal government is still in the process of implementing this change. For an estimate of the impact of these changes, see generally OFF. OF INSPECTOR GEN., ANALYZING CHANGES TO MEDICAID FEDERAL UPPER LIMIT AMOUNTS (2012), <http://oig.hhs.gov/oei/reports/oei-03-11-00650.pdf>.

was paid a flat amount for acquiring the dispensed drug, *irrespective of its actual acquisition cost*. But some state Medicaid program directors believed they were still overpaying for many drugs. Those states responded by adopting MAC programs, which were similar to FULs, but applied to a far broader array of drugs, and set lower reimbursement levels.<sup>38</sup> Medicaid MACs are calculated based on aggregate figures that reflect pharmacies' average acquisition cost for a given pharmaceutical product. As of January 12, 2012, all states used FULs and approximately forty-five states used MACs in their Medicaid programs.<sup>39</sup>

For drugs not subject to FULs and MACs, states implemented additional cost control measures, including paying pharmacies based on published Wholesale Acquisition Costs ("WACs"), or applying a standardized discount to published AWP. In combination, these measures brought the amounts paid for pharmaceuticals closer to the actual acquisition costs incurred by pharmacies.

#### D. Private Sector Use of MACs

PBMs use contracts to create pharmacy networks. Approximately 95 percent of the nation's retail pharmacies are included in one or more PBM pharmacy networks. A pharmacy that joins a network agrees to accept the terms in their contract (often called a Participating Pharmacy Agreement ("PPA")). The PPA specifies how pharmacies will be reimbursed, details the nature of any MACs that may apply, and spells out the process for resolving disputes. Pharmacies are free to decline to contract with an insurer/PBM for whatever reason they choose—including inadequate reimbursement, uncertainty about the level of reimbursement, or the "hassle factor" of dealing with a particular insurer/PBM.

In designing and implementing a PPA, the PBM must balance two competing goals: (1) it wants to ensure a broad network of pharmacies at which prescriptions may be filled (because ease of access to covered services is one of the "products" the PBM sells to payors), but (2) it also has to control the cost of the covered services (because low cost is also one of the "products" the PBM sells). If a PBM errs in one direction (e.g., through overly generous payments for pharmaceuticals), it will ensure a broad network of pharmacies, but the covered services will be less affordable—meaning the PBM may not get the business for which it is

---

38. Richard G. Abramson et al, *Generic Drug Cost Containment in Medicaid: Lessons from Five State MAC Programs*, 25 HEALTH CARE FINANCING REV. 25, 25 (2004).

39. OFFICE OF INSPECTOR GEN., MEDICAID DRUG PRICING IN STATE MAXIMUM ALLOWABLE COST PROGRAMS 5–6 (2013), <https://oig.hhs.gov/oei/reports/oei-03-11-00640.pdf>.

bidding. Conversely, if the PBM errs in the other direction (e.g., through inadequate payment for pharmaceuticals, excessive hassle factor or DIR fees, and the like), pharmacies will decline to contract, drop out of the PBMs' network, or refuse to stock a sufficient supply of the pharmaceuticals for which they deem the MAC payment to be insufficient. Employers and employees will not value a pharmacy network that is too limited along any of these dimensions—meaning the PBM may not get the business for which it is bidding.

When properly designed, MACs help PBMs steer a middle ground between these two extremes. By paying the average acquisition costs incurred by a well-run pharmacy, MACs create the necessary incentive for pharmacies to purchase and dispense of the lowest-priced generics that are available in the market. Of course, periodic adjustments are necessary to deal with unanticipated or extraordinary circumstances, but market forces serve to discipline overreaching by all involved parties (e.g., pharmacies, PBMs, and employers/employee benefit plans).

### *E. The Effect of MACs: A Dose of Theory*

MACs have at least five distinct effects. First, MACs encourage pharmacies to dispense the generic version of applicable pharmaceuticals. Second, MACs heighten competition among generic manufacturers. Third, MACs help ensure that pharmacies are not being overpaid for the services they provide. Fourth, MACs lower spending on pharmaceutical benefits, thereby reducing the cost of prescription drug coverage. Finally, MACs make prescription drug reimbursement more efficient.

#### 1. Incentivizing Pharmacies to Dispense Generics

When pharmacies are only paid the amount specified in the MAC, they have a substantially increased incentive to acquire and dispense generic drugs.<sup>40</sup> This dynamic means that a MAC will increase the share of generic drugs that are dispensed, compared to a pure cost-based reimbursement system. In the absence of a MAC, the pharmacy's incentives are quite different because it will be paid based on a "list" price that often bears little resemblance to the actual acquisition cost. Under those circumstances (i.e., absent a MAC) a pharmacy that dispenses a higher-priced drug (i.e., the brand name version) will actually be paid more, thus increasing the cost of providing prescription drug benefits

---

40. *Id.* at 5 ("Because pharmacy reimbursement is based on a single [maximum allowable cost ("MAC")] price (regardless of whether a generic or brand version of a drug is dispensed), the program creates a financial incentive to substitute lower-cost generic equivalents for their brand-name counterparts.").

without providing any commensurate benefits.

## 2. Increasing Competition Among Generic Manufacturers

When pharmacies only receive the amount specified in the MAC, they have an increased incentive to “shop for the best deal,” and find generic drugs at the lowest possible price (because they get to keep the difference between the acquisition price and the MAC). This heightens price competition among generic drug manufacturers and drug wholesalers, who know that offering lower-priced generics will help drive more sales.

Absent a MAC, pharmacies have a lower incentive to buy the lowest-cost generic because their reimbursement is based on the “list” price (which, as noted above, often bears little relationship to the acquisition cost). Under those circumstances, pharmacies will predictably seek to maximize the difference between the “list” price and their actual cost, rather than simply buying the lowest-cost generic.

## 3. Ensuring Pharmacies Are Not Overpaid

Cost-based reimbursement can lead to various forms of gaming that result in excess payments to pharmacies. For example, pharmacies have an incentive to dispense higher-priced drugs, particularly if they are paid a percentage markup on their incurred costs. MACs help prevent this behavior, and ensure that the requisite services are obtained at a level consistent with actual costs.

## 4. Lowering Prescription Drug Spending and the Cost of Prescription Drug Coverage

When we combine the first three effects with the lower price at which generics are dispensed, it becomes clear that MACs help lower prescription drug spending, which in turn reduces the cost of prescription drug coverage. In an analysis of Medicaid MACs, the Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”) concluded that MACs had “significant value” in “containing Medicaid drug costs.”<sup>41</sup> The OIG also noted that if all states adopted the strictest MAC program that was used in 2011, generic drug spending would decline by more than 20 percent in fourteen states, and total Medicaid pharmaceutical spending would be \$966 million lower.<sup>42</sup>

## 5. Enhanced Market Efficiency

Each drug manufacturer has its own unique “list” price for every

---

41. *Id.* at 21 (“Our findings demonstrate the significant value MAC programs have in containing Medicaid drug costs.”).

42. *Id.* Wyoming’s MAC program resulted in the greatest aggregate savings.

dosage and variation of each drug that they sell. As discussed previously, these “list” prices vary widely, and bear little relationship to pharmacies’ actual acquisition cost. A MAC cuts through the forest of individual “list” prices, and specifies the reimbursement that will be paid, regardless of the “list” price and the actual acquisition cost. Payors need not inquire into the specifics of individual transactions, and instead will simply pay the standardized amount. By eliminating the need to conduct individualized assessments, MACs help lower transaction costs and structure the market more efficiently, thereby improving system performance.

#### *F. Legislative Efforts*

As detailed in the Appendix, in the last three years, thirty-seven states adopted MAC-related legislation.<sup>43</sup> These statutes vary in their details, but many require public disclosure of each PBMs’ MACs and the methodology for arriving at the amounts that will be paid; limit the circumstances in which MACs may be used (i.e., by requiring a certain number of A-rated equivalents); require the submission of proprietary information regarding MACs to public authorities; and specify particular methods and time frames for MAC appeals and payment adjustments, including requiring retroactive payments. In a few instances, states require PBMs to reimburse the actual acquisition costs that are incurred, even if a cheaper alternative was available in the marketplace.

#### *G. Likely Effects of MAC Legislation*

From a competition law perspective, none of these initiatives are likely to improve the performance of the pharmaceutical market, and most seem likely to make things worse. First, restrictive state-specific criteria undermine the flexibility of PBMs to develop and implement MACs. Mandatory public disclosure of MACs and the specifics of the underlying methodologies are unlikely to benefit consumers because both will probably lead to less intensive competition and higher prices.<sup>44</sup>

---

43. In addition, federal legislation was proposed, but was not enacted. Medicare Prescription Drug Program Integrity and Transparency Act of 2013, S. 867, 113th Cong. (2013), <https://www.congress.gov/bill/113th-congress/senate-bill/867>.

44. In pharmaceutical markets, the intensity of competition is a function of various factors, including the ability of a pharmacy benefit managers (“PBM”) to obtain a competitive advantage by developing more effective MACs. Forced disclosure of MAC methodologies may undermine PBMs’ incentive to invest in such efforts (because other PBMs will be able to free ride). In that environment, PBMs will be less likely to innovate—meaning that MACs will be less effective than they could be. Stated differently, compelled disclosure can create a risk to competition, which is likely to result in higher prices for consumers.



Requiring specific methods and time frames for MAC appeals and payment adjustments—including requiring “retroactive” payments—is also likely to have unintended effects. Such provisions seem likely to result in administrative complexity and unpredictability, which will in turn result in increased costs.

The provisions that require PBMs to pay at least actual acquisition costs are particularly pernicious. The inflationary consequences of cost-based reimbursement are well known and help explain why such reimbursement schemes have fallen into disfavor in health care.<sup>45</sup> The

The FTC has studied these issues, and issued three detailed advocacy letters in 2004, 2006, and 2011 on the impact of mandated disclosure of PBM contract terms. Letter from Susan A. Creighton, Dir., Bureau of Competition, Fed. Trade Comm’n, to Greg Aghazarian, Assembly Member (Sept. 7, 2004), [https://www.ftc.gov/sites/default/files/documents/advocacy\\_documents/ftc-comment-hon.greg-aghazarian-concerning-ca.b.1960-requiring-pharmacy-benefit-managers-make-disclosures-purchasers-and-prospective-purchasers/v040027.pdf](https://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-comment-hon.greg-aghazarian-concerning-ca.b.1960-requiring-pharmacy-benefit-managers-make-disclosures-purchasers-and-prospective-purchasers/v040027.pdf); Letter from Susan S. DeSanti et al., Dir., Office of Policy Planning, Fed. Trade Comm’n, to Mark Formby, Representative, Miss. House of Representatives (Mar. 22, 2011), [https://www.ftc.gov/sites/default/files/documents/advocacy\\_documents/ftc-staff-letter-honorable-mark-formby-mississippi-house-representatives-concerning-mississippi/110322mississippipbm.pdf](https://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-letter-honorable-mark-formby-mississippi-house-representatives-concerning-mississippi/110322mississippipbm.pdf); Letter from Maureen K. Ohlhausen, Dir., Office of Policy Planning, Fed. Trade Comm’n, to Terry G. Kilgore, Member, Commonwealth of Va House of Delegates (Oct. 2, 2006), [https://www.ftc.gov/sites/default/files/documents/advocacy\\_documents/ftc-staff-comment-hon.terry-g.kilgore-concerning-virginia-house-bill-no.945-regulate-contractual-relationship-between-pharmacy-benefit-managers-and-both-health-benefit/v060018.pdf](https://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-comment-hon.terry-g.kilgore-concerning-virginia-house-bill-no.945-regulate-contractual-relationship-between-pharmacy-benefit-managers-and-both-health-benefit/v060018.pdf).

The FTC and Department of Justice also issued a lengthy joint report on health care and competition policy in 2004 that discussed these issues, and a report in 2005 that provided extensive information on PBM operations. See generally FTC-DOJ, IMPROVING, *supra* note 3 (noting the 2004 joint report); FED. TRADE COMM’N, PHARMACY BENEFIT MANAGERS: OWNERSHIP OF MAIL-ORDER PHARMACIES (2005), <http://www.ftc.gov/reports/pharmbenefit05/050906pharmbenefitrpt.pdf> (noting the 2015 report). To be sure, the FTC was studying a different set of issues, but the risks to competition of compelled transparency are analogous. One of us (Hyman) was a co-author of the 2004 advocacy letter, and both of us worked on the FTC-DOJ report.

45. Prior to 1983, Medicare relied on cost-based reimbursement for inpatient hospitalization. Medicare payments were accordingly based on whatever costs the hospital incurred—and each hospital had virtually complete freedom to determine its own cost structure. The result was entirely predictable: Medicare costs for inpatient treatment skyrocketed, as hospitals determined that there were no effective constraints on the amounts they could bill, as long as they had legitimately incurred the associated costs.

After the consequences of cost-based reimbursement became clear, a bipartisan consensus in favor of a different payment system emerged. In 1983, Medicare switched to a prospective payment system (“PPS”), which paid a standardized amount, irrespective of the actual costs incurred by the hospital. A small number of hospitals were excluded from the PPS. But payment for the overwhelming majority of hospitals switched virtually overnight from cost-based reimbursement to the PPS.

Hospitals suddenly had an incentive to pay attention to the costs they incurred for treating each patient, instead of simply passing those costs on. Although there have been issues with the

same dynamic has played out in the context of government procurement.<sup>46</sup> The problems with cost-based contracts were well known to defense contractors and to Congress.<sup>47</sup> Federal procurement regulations now specify that cost-based reimbursement contracts may only be used when the contracting officer certifies that a fixed-price type contract cannot be used.<sup>48</sup>

In sum, restrictions on the use of MACs that push pharmaceutical purchasing toward cost-based reimbursement will lead to increases in pharmaceutical spending and increases in the cost of prescription drug coverage. The magnitude of these increases is obviously subject to considerable uncertainty,<sup>49</sup> but the directional effect seems clear.

---

implementation of PPS, there has been no serious discussion of a return to cost-based reimbursement for hospitals.

46. For many years, the federal government used cost-based procurement for defense contracts. Unfortunately, this approach created little incentive for defense contractors to perform in the most efficient way possible, because they knew their costs would be reimbursed, *however much they were*. Cost-based reimbursement also meant that the government assumed most of the risks of performance, because it had agreed to pay the contractor its full allowable incurred costs until the job was accomplished, or the contract was terminated. Unsurprisingly, cost-based contracts sometimes resulted in sizeable cost overruns (relative to the originally estimated and budgeted cost) for defense procurement.

47. A book by then-Representative Henry Waxman concisely summarizes the prevailing wisdom on the perils of cost-based reimbursement: “One Halliburton official told us that the company’s mantra was ‘Don’t worry about price. It’s ‘cost-plus.’ One needn’t be a math whiz to understand how quickly this system inflates costs and even gives contractors an incentive to run up enormous bills.” HENRY WAXMAN, *THE WAXMAN REPORT: HOW CONGRESS REALLY WORKS* 155 (2009).

48. 48 C.F.R. § 16.301-2 (2012). More specifically, the contracting officer must certify that the circumstances do not allow the agency to define its requirements sufficiently to allow for a fixed-price type contract; or the uncertainties involved in contract performance do not permit costs to be estimated with sufficient accuracy to use any type of fixed-price contract. And, when a cost-based contract is used, the contracting officer is required to employ appropriate surveillance measures, to provide assurance that efficient methods and effective cost controls are in place. *Id.* § 16-301-3(a).

49. We have located two attempts to “score” the impact of state-level regulation of MACs. One study, conducted by Visante, estimated that spending on the affected pharmaceuticals would increase by 31–56 percent, with a nationwide impact of \$6.2 billion increased spending annually. VISANTE, *PROPOSED MAC LEGISLATION MAY INCREASE COSTS OF AFFECTED GENERIC DRUGS BY MORE THAN 50 PERCENT* 2 (2015). Importantly, this estimate captures only the immediate fiscal impact, and not the more long-term indirect consequences.

The second study was performed by the Washington Health Care Authority (“WHCA”), and involved “scoring” the financial impact of proposed legislation that prohibited PBMs from paying pharmacies less than their actual acquisition cost. WHCA concluded the proposed legislation would make MAC lists much less effective, and would dramatically reduce pharmacies’ incentive to acquire generic drugs at the lowest possible cost. Multiple Agency Fiscal Note Summary, S.B. 5857, 64th Leg., Reg. Sess. (Wash. 2015). Although WHCA did not settle on a single number for the fiscal impact of S.B. 5857, it presented a range of figures, up to and including a 10 percent increase in the cost of pharmaceuticals. WHCA specifically determined that the legislation would

### H. *How the Empire Struck Back: The Political Economy of MAC Legislation*

How did such overtly anticompetitive legislation get enacted in such short order, and by so many states? A fundamental insight of health policy is that every dollar of health care spending is a dollar of income for health care providers.<sup>50</sup> To the extent that MACs are effective at reducing pharmaceutical spending on generic drugs, they reduce the amounts that pharmacies receive for dispensing those same drugs. Not surprisingly, pharmacists feel aggrieved that their services are not being compensated at the handsome level that they believe their expertise and professionalism justify—and they lobby for relief from the hardships imposed by competitive markets.

Pharmacists began these lobbying campaigns with at least three distinct advantages. First, like funeral directors and car dealerships, there are one or more pharmacies in every legislative district, many of which are small independent pharmacies. These small independent pharmacies are pillars of the local business community. Second, if a legislator has to pick sides, the small independent local pharmacy is a much more appealing entity than a large, out-of-state PBM. Third, many legislators believe there is a serious problem with access to pharmacy care in rural areas where most pharmacies are small and independent.

Although chains account for a near majority of pharmacies in most states, the protection of small independent local pharmacies from the depredations of large out-of-state PBMs was the basis of the lobbying campaign. The flames were fanned by references to the rebates that PBMs were receiving from drug companies.<sup>51</sup> Given these dynamics, it is not surprising that we went from *no* states with MAC legislation at the beginning of 2013 to thirty-seven states having such legislation only three and a half years later.

#### 1. Consequential Features of MAC Legislation

Three features of the MAC statutes listed in the Appendix deserve further attention. First, although the legislative campaign was built

---

“significantly increase” costs for public employee benefits and would also have a cost-increasing impact on Medicaid.

50. Hyman, *Getting the Haves*, *supra* note 16, at 280 (noting “the reality that every dollar of health care spending by someone is a dollar of income for someone else”).

51. These rebates are paid on branded drugs—not generics—so it is difficult to see the relevance of this argument to a dispute over whether PBMs are paying pharmacies the right amount for dispensing generic drugs. And, the fact that PBMs may have multiple sources of revenue does not translate into a legal or ethical obligation to share any of that revenue with pharmacies. Instead, competitive dynamics determine how much PBMs must pay to induce pharmacies to participate in a PBM’s network.

around the protection of independent (mostly rural) pharmacies, state MAC statutes were not so limited. Instead, in all of these jurisdictions, every single pharmacy—including chain drugstores in urban locations—receives the benefits of the legislation. That strategy means the legislation is not well targeted to address the supposed problem that it is allegedly remedying. Stated differently, MAC legislation puts money in the pockets of all pharmacies in a state, regardless of whether they “need” it or not. To say the least, that is an exceedingly peculiar understanding of “consumer protection.”

Second, in thirty-six of the thirty-seven states, the state Medicaid program is excluded from the requirements imposed by the MAC legislation.<sup>52</sup> Many of these states also exclude state employees from the “consumer protections” contained in the MAC statutes. The only thing these two groups have in common is that the costs of their health coverage are on-budget expenses, borne (either in whole or in part) by the state in its sovereign capacity. By excluding these populations from the scope of MAC legislation, state legislators made it clear that they thought the supposed consumer protections were worth doing—right up until the moment the state would bear the costs of doing so. This pattern is certainly not unique to MAC legislation, but it provides a useful (albeit underinclusive) signal of legislation that is provider protection masquerading as consumer protection.<sup>53</sup>

Finally, in some states, the legislative history casts light on whose interests are actually being protected. When Iowa was considering MAC legislation, one overly enthusiastic legislator stated that the legislation was necessary because the lack of regulation was “eroding local pharmacies.”<sup>54</sup> Another Iowa legislator explained that legislation was necessary because PBMs were engaging in “unfair business practices that hurt community pharmacies and their patients.”<sup>55</sup> Similarly, when Washington enacted MAC legislation, the Office of Insurance Commissioner was instructed to conduct a study that would, *inter alia*, “discuss suggestions that recognize the unique nature of small and rural

---

52. The exceptions are Mississippi and Texas.

53. David A. Hyman, *Drive-Through Deliveries: Is Consumer Protection Just What the Doctor Ordered?*, 78 N.C. L. REV. 5, 25–26 (1999) (noting that the majority of the states that enacted prohibitions on drive-through deliveries excluded state employees and Medicaid beneficiaries from the statute).

54. Pharm. Care Mgmt. Assoc. v. Gerhardt, No. 4:13-cv-000345, 2015 WL 10767327, at \*3 (S.D. Iowa Sept. 8, 2015), <http://www.ncpa.co/pdf/iowa-order-granting-motion-to-dismiss-as-to-remaining-claims.pdf> (order).

55. *Id.*

pharmacies and possible options that support a viable business model that do not increase the cost of pharmacy products.”<sup>56</sup> As these examples indicate, MAC legislation is provider protection—not consumer protection.

## 2. Some Empirical Evidence

The legislative campaign against MACs turned on whether pharmacies were being paid enough for dispensing generic drugs, with the two sides staking out competing positions on various factual matters.

Pharmacies insisted that PBMs were underpaying them, by setting MAC levels too low, and failing to update them quickly enough when acquisition costs increased. Pharmacies argued that the resulting shortfalls in payment placed considerable financial pressure on independent pharmacies (particularly those in rural areas), causing closures and more limited access to pharmacy services.

PBMs insisted that they were paying the correct amounts. They argued that pharmacies that were losing money on dispensed generic prescriptions were either paying higher acquisition costs than they needed to; were mistaken about the transactions in question; or did not realize that MACs were intended to average out across all the generic prescriptions dispensed by a well-run pharmacy, with over-payments on some drugs compensating for under-payments on others.

What do we actually know about these issues (i.e., MAC usage and levels, and access to pharmacy services)? We consider each in turn.

### a. MAC Usage and Levels

One of us (Professor Hyman) interviewed personnel at four PBMs about their use of MACs during April and May 2016.<sup>57</sup> All four PBMs used MACs for most drugs that were available in generic form. MACs were typically set for each generic drug in all of the available dosing strengths. MAC levels were set based on pricing information from various sources, including Medicaid MAC and FUL lists; and price lists from wholesalers and other sources (e.g., National Average Drug Acquisition Cost (“NADAC”) and Medi-Span). All four PBMs used this pricing information to create their own MAC lists—each using its own proprietary methods. Each PBM maintained multiple MAC lists, which varied depending on the contracts with plan sponsors. Some MAC lists were regional, but most were applied on a national basis. All four PBMs

---

56. S.B. 5857, 64th Leg., Reg. Sess. (Wash. 2015).

57. The interviews were conducted with a promise of confidentiality, so we are unable to identify the four PBMs that participated in the study.

insisted that they took account of changes in drug acquisition costs in updating their MAC lists—in some instances doing so on a daily basis.

Each PBM had its own appeals mechanism. Appeals were triggered when a pharmacy submitted documentation confirming that the drug was actually dispensed to a PBM customer, and that the MAC was below the pharmacy's actual acquisition cost. All of the PBMs used the information derived from appeals as part of a feedback loop to inform the levels at which MACs were set. All four PBMs reported that appeals were a small share (i.e., much less than 1 percent) of the total transactions they handled.

Of course, there are limitations to qualitative studies of this sort. None of those being interviewed were under oath. MACs are a hot issue, and those being interviewed were unlikely to volunteer information that would make their employers look bad. Qualitative research can provide information about how PBMs create and maintain their MAC lists—but only quantitative research can answer the question of how often PBMs pay pharmacies less (and more) than their acquisition cost; how large those deviations actually are; whether there are any time trends in these patterns; and whether the drugs in question were available for less from a different wholesaler than the one used by the pharmacy in question.

It is exceedingly difficult to conduct such research because the pharmaceutical marketplace is quite dynamic, data from multiple sources is required, and all of the PBMs treat their MAC lists as proprietary and confidential. Notwithstanding those difficulties, Washington's 2016 MAC legislation required the Washington Office of Insurance Commissioner to conduct a quantitative study of these issues.<sup>58</sup> The report, which was published in February 2017, gave some support to both sides in the debate.<sup>59</sup> But regardless of the results of such studies, from an economic perspective what matters is whether pharmacies are willing to participate in the networks that PBMs have created, and whether those networks are acceptable to payors. Everything else is sound and fury,

---

58. S.B. 5857, 64th Leg., Reg. Sess. (Wash. 2015).

59. HEALTH MGMT. ASSOCS., STUDY OF THE PHARMACY CHAIN OF SUPPLY 34 (2016), <https://www.insurance.wa.gov/current-issues-reform/pharmacy-benefit-managers/documents/pharmacy-supply-chain-study.pdf>. More specifically, the study found that the number of drugs that were on a PBM's MAC list "varied significantly" across PBMs; MAC lists resulted in "payments to pharmacies that are higher than the [National Average Drug Acquisition Cost ("NADAC")] benchmark price and lower than the regional benchmark prices;" one PBM "paid rural pharmacies less than all benchmarks," while two PBMs paid more; and five of the six PBMs that were studied "paid independent pharmacies more than chain drug stores in the NADAC analysis." *Id.* at 35.

signifying nothing.<sup>60</sup>

### b. Access to Pharmacy Services

Pharmacists obviously care a great deal about whether their pharmacy closes its doors, and whether it is operated by a chain or is independent. But it is less obvious that anyone else should be all that invested in those issues. We should care about whether patients have access to pharmacy services, and not nearly as much (if at all) about the specifics of how those services are delivered. And, we should know more about the relevant size of the geographic market for pharmacy services before concluding any given pharmacy closure is a problem.<sup>61</sup>

That said, there is evidence that there have been a material number of closures of rural pharmacies.<sup>62</sup> But, this trend long pre-dates the recent dispute over MAC levels, and the number of closures was much higher in 2007–09, with subsequent trends “not as pronounced or as clear as in earlier years.”<sup>63</sup> More importantly, a recent study of access to pharmacy services for Medicare Part D beneficiaries by the Centers for Medicare and Medicaid Services found that 99 percent of urban beneficiaries had access to a pharmacy within two miles; 99 percent of suburban beneficiaries had access to a pharmacy within five miles; and 97 percent of rural beneficiaries had access to a pharmacy within fifteen miles.<sup>64</sup>

60. WILLIAM SHAKESPEARE, *MACBETH* act 5, sc. 5 (“[I]t is a tale Told by an idiot, full of sound and fury, Signifying nothing.”).

61. For example, when Illinois was debating tort reform in 2003–05, it was routinely noted that there were no neurosurgeons south of Springfield. No one ever discussed whether we actually should be concerned about the number of neurosurgeons south of Springfield—particularly when Carbondale, Illinois is closer to St. Louis, Missouri (96 miles) than to Springfield, Illinois (160 miles).

62. See, e.g., Kelli Todd et al., *Rural Pharmacy Closures: Implications for Rural Communities*, RUPRI Brief No. 2012-5 (Jan. 2013), <https://www.public-health.uiowa.edu/rupri/publications/policybriefs/2013/Pharmacist%20Loss%20Brief%20022813.pdf>.

63. Fred Ullrich & Keith Mueller, *Update: Independently Owned Pharmacy Closures in Rural America, 2003–2013*, RUPRI Brief No. 2014-7 (June 2014), <http://cph.uiowa.edu/rupri/publications/policybriefs/2014/Pharm%20Closure%20Brief%20June%202014.pdf>. See also Donald Klepser et al., *Independently Owned Pharmacy Closures in Rural America*, RUPRI Brief No. 2008-2 (July 2008), <http://cph.uiowa.edu/rupri/publications/policybriefs/2008/b2008-2%20Independently%20Owned%20Pharmacy%20Closures.pdf> (researching why independently owned pharmacies in rural America closed).

64. CTRS. FOR MEDICARE & MEDICAID SERVS., *ANALYSIS OF PART D BENEFICIARY ACCESS TO PREFERRED COST SHARING PHARMACIES (PCSPS)* 5 (2015), <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/PCSP-Key-Results-Report-Final-v04302015.pdf>.

These findings suggest that pharmacy closures have not had a material impact on access to pharmacy services.

#### IV. DISCUSSION

##### *A. How Representative Are MACs?*

This Article presents a single case study. Readers might well ask whether we cherry-picked a particularly egregious example of rent seeking to justify our conclusions. We do not believe that our findings are skewed by the specific example we have chosen. In previous work, we examined other examples of health care regulation, including restrictions on entry (i.e., licensure and certificates of need/public necessity) and restrictions on the terms for which goods and services may be provided (i.e., mandated benefits, any willing provider legislation, and other planks in what used to be known as the “patient bill of rights”). The MAC-related findings presented in this Article are fully consistent with the findings in our earlier work.

Other scholars have reached similar conclusions about health care legislation and regulation.<sup>65</sup> And there is rich public choice literature documenting that similar complaints may be lodged at legislation and regulation across all substantive areas of law and policy. Whatever one might want to say in defense of MAC statutes, they fit comfortably into a rich tradition, where “the favored pastime of state and local governments” is the “dishing out [of] special economic benefits to certain in-state industries.”<sup>66</sup>

##### *B. Balance This!*

The symposium at which this Article was presented was framed around the optimal balance between competition and consumer protection. That issue is obviously difficult and complex, and no one has come up with a perfect solution to the problem. That is why it provides a good subject for a symposium. Balancing competition against provider protection masquerading as consumer protection is another matter entirely. That problem is easy.<sup>67</sup> Indeed, most of what passes as consumer protection in health care is, in fact, provider protection. We should stop pretending otherwise.

---

65. Clark C. Havighurst & Barak D. Richman, *Distributive Injustice(s) in American Health Care*, 69 LAW & CONTEMP. PROBS. 7, 8–9 (2006).

66. Powers v. Harris, 379 F.3d 1208, 1221 (10th Cir. 2004).

67. See Burnham v. Superior Court, 495 U.S. 604, 640 (1990) (Stevens, J., concurring) (“Perhaps the adage about hard cases making bad law should be revised to cover easy cases.”).



### C. Implications of Our Analysis for the State Action Doctrine

Our findings obviously call into question both the scope of the state action doctrine and the deference that doctrine gives to the decisions of state legislators. MAC statutes exemplify the degree to which private economic actors are willing and able to enlist state authority to obstruct entry or otherwise restrict competitive threats to incumbent market participants.<sup>68</sup> And, as noted previously, these efforts make perfect sense.<sup>69</sup> The relentless expansion of criminal antitrust enforcement has created powerful incentives for firms to seek comfort from state legislators.<sup>70</sup> Privately agree with your competitors to exclude rivals, and you may go to jail; get the state to do it for you, and it is the competitors who may face a prison sentence for failing to comply.

State action also has distributional consequences—including spillover anticompetitive effects in other states. The benefits of MAC legislation are captured by in-state pharmacies, but the costs are largely externalized to out-of-state PBMs—particularly during the term of lock-in contracts between PBMs and payors.<sup>71</sup> Previous commentators have noted the importance of limiting state action immunity to laws that have little or no spillovers into other states.<sup>72</sup> Retrenchment of the state action doctrine, along with closer and more skeptical scrutiny of state-based restrictions on competition would reflect the reality that the limits imposed by one state routinely damage the interests of citizens in other states—particularly when electronic commerce has diminished the amount of commerce that is truly “local.”

For those who are concerned with distributive (in)justice, health care regulation exemplifies the various ways in which “the haves come out ahead.”<sup>73</sup> Of course, such reverse-Robin Hood schemes are not limited

---

68. The expansion of state licensure requirements is documented in Aaron Edlin & Rebecca Haw, *Cartels by Another Name: Occupational Licensing and the Quality of Service*, 162 U. PA. L. REV. 1093, 1102–03 (2014); Paul J. Larkin, Jr., *Public Choice Theory and Occupational Licensing*, 39 HARV. J.L. & PUB. POL’Y 209, 212 (2016).

69. See *supra* note 1 and accompanying text.

70. James C. Cooper & William E. Kovacic, *U.S. Convergence with International Competition Norms: Antitrust Law and Public Restraints on Competition*, 90 B.U. L. REV. 1555, 1561–62 (2010).

71. PBMs contract with plan sponsors on either a “pass-through” or a “lock-in” basis. A lock-in contract obligates the PBM to hit the contractually specified targets throughout the contractual term, irrespective of changes in the pharmaceutical market—including changes in the amounts that must be paid to dispensing pharmacies because of state MAC statutes.

72. Robert P. Inman & Daniel L. Rubinfeld, *Making Sense of the Antitrust State Action Doctrine: Balancing Political Participation and Economic Efficiency in Regulatory Federalism*, 75 TEX. L. REV. 1203, 1217–18 (1997).

73. See *supra* note 16 and accompanying text.

to health care. Many of the state restrictions that have been challenged by the DOJ and FTC, whether through litigation or competition advocacy, have perverse (i.e., upside down) distributional effects.<sup>74</sup>

Perhaps there is something to be learned from the ways in which other countries handle these matters. Many countries closely scrutinize anticompetitive state measures, and intervene forcefully to strike them down.<sup>75</sup> Other jurisdictions do allow political subdivisions to restrict competition, but they subject such interventions to more demanding standards and more frequently invalidate them.<sup>76</sup> For example, the European Commission places sharp limits on when a jurisdiction can provide “state aid,” including an ex ante approval process that is back-stopped by the availability of recoupment and restitution.<sup>77</sup> These approaches more fully address the destructive potential of state curbs on competition than the “nothing to see here, move along” approach taken by the United States in its implementation of the state action doctrine.

#### CONCLUSION

Our proposal is modest. We should begin by acknowledging two simple facts: (1) virtually everything that is billed as “consumer protection” in the health care space is actually “provider protection”; and (2) the state action doctrine insulates such conduct, as well as other forms of rent seeking from antitrust scrutiny—at least as long as the state can satisfy the minimal hurdles created by the clear articulation and active supervision requirements.

The antitrust laws work reasonably well in dealing with private anticompetitive conduct, but the state action doctrine turns the antitrust laws into a goalie that only guards half the net.<sup>78</sup> That approach is not working, and cannot be made to work. To continue our metaphor, players quickly learn to shoot at the unguarded half of the net.<sup>79</sup> We should treat provider protection as a form of state aid, and use the competition laws to strike down a substantially greater share of the rent-seeking statutes

---

74. Cooper & Kovacic, *supra* note 70, at 1565.

75. Eleanor M. Fox & Deborah Healey, *When the State Harms Competition—The Role for Competition Law*, 79 ANTITRUST L.J. 69, 69–70 (2014).

76. Cooper & Kovacic, *supra* note 70, at 1584–85.

77. *State Aid Control*, EUR. COMMISSION, [http://ec.europa.eu/competition/state\\_aid/overview/index\\_en.html](http://ec.europa.eu/competition/state_aid/overview/index_en.html) (last updated Dec. 9, 2016).

78. We leave it up to the reader to decide whether the hypothetical goalie is playing hockey, lacrosse, soccer, or water polo.

79. See Muris, *supra* note 1, at 2 (noting that “as a competition system achieves success in attacking private restraints, it increases the efforts that firms will devote to obtaining public restraints”).

that emerge from the legislative process. Of course, the toolkit for fixing these problems is not limited to competition law. The list of “fixes” should also include greater public scrutiny, routine-sun-setting, and a healthy dose of skepticism about the operations of the administrative state.<sup>80</sup>

What about the problem of striking the proper balance between true consumer protections and competition? And, the obligations imposed by federalism? Get back to us once the system has been purged of provider protection. Until then, we all have bigger fish to catch, kill, and fry.

---

80. Hyman & Svorny, *supra* note 7, at 111.

## APPENDIX: States with MAC Statutes

<b>State</b>	<b>MAC Statute</b>
<b>Arkansas</b>	ARK. CODE ANN. § 17-92-507 (2013)
	S.B. 688, 90th Gen. Assemb., Reg. Sess. (Ark. 2015)
<b>California</b>	Assemb. B. 627, 2015-2016 Leg., Reg. Sess. (Cal. 2015)
<b>Colorado</b>	COLO. REV. STAT. § 25-37-103.5 (2016)
<b>Delaware</b>	DEL. CODE ANN. tit. 18, §§ 3301A–3310A (West 2016)
<b>Florida</b>	FLA. STAT. ANN. § 465.1862 (West 2015)
<b>Georgia</b>	H.B. 470, 2015–2016 Leg., Reg. Sess. (Ga. 2015)
<b>Hawaii</b>	HAW. REV. STAT. ANN. § 328-106 (West 2015).
<b>Iowa</b>	IOWA CODE § 510B.8 (2014)
<b>Kansas</b>	KAN. STAT. ANN. § 40-3822 (West 2016).
<b>Kentucky</b>	KY. REV. STAT. ANN. § 304.17A.162 (West 2013)
	KY. REV. STAT. ANN. § 304.9-020 (West 2016)
<b>Louisiana</b>	LA. REV. STAT. ANN. § 22:1863 (2014)
	LA. REV. STAT. ANN. § 22:1864 (2014)
	LA. REV. STAT. ANN. § 22:1865 (2014)
<b>Maine</b>	ME. REV. STAT. ANN. tit. 24-A, § 4317 (2016)
<b>Maryland</b>	MD. CODE ANN., INS. § 15-1628.1 (2014)
<b>Minnesota</b>	MINN. STAT. § 151.71 (2014)
<b>Mississippi</b>	MISS. CODE ANN. § 73-21-155(West 2016)
<b>Missouri</b>	MO. ANN. STAT. § 376.388 (West 2016)

<b>Montana</b>	MONT. CODE ANN. §§ 33-22-170–33-22-173 (2017)
<b>New Hampshire</b>	H.B. 1664, Gen. Assemb., 2015 Sess. (N.H. 2016)
<b>New Jersey</b>	N.J. STAT. ANN. § 17B:27F (West 2016)
<b>New Mexico</b>	N.M. STAT. ANN. § 59A-61-4 (2014)
<b>New York</b>	N.Y. PUB. HEALTH LAW § 280-a (McKinney 2016)
<b>North Carolina</b>	N.C. GEN. STAT. § 58-56A-5 (2014)
<b>North Dakota</b>	N.D. CENT. CODE § 19-02.1-14.2 (2013)
<b>Ohio</b>	OHIO REV. CODE ANN. § 3959.111 (West 2015)
<b>Oklahoma</b>	OKLA. STAT. ANN. tit. 59, §§ 357, 360 (West 2016)
<b>Oregon</b>	OR. REV. STAT. § 735.534 (2013)
<b>Rhode Island</b>	27 R.I. GEN. LAWS ANN. § 27-28-33.2 (West 2016)
<b>South Carolina</b>	S.C. CODE ANN. §§ 38-71-2110, 38-71-2120, 38-71-2130, 38-71-2140
<b>Tennessee</b>	TENN. CODE ANN. §§ 56-7-3106, 56-7-3111 (2015)
	TENN. CODE ANN. § 56-7-3102 (2016)
<b>Texas</b>	TEX. GOV'T CODE ANN. § 533.005 (West 2013)
	TEX. INS. CODE ANN. §§ 1369.35–1369.362 (2016)
<b>Utah</b>	UTAH CODE ANN. § 31A-22-640 (West 2014)
<b>Vermont</b>	VT. STAT. ANN. tit 18, §§ 9471, 9473 (West 2015)
<b>Virginia</b>	VA. CODE ANN. § 38-2-3407.15:3 (2015)
<b>Washington</b>	WASH. REV. CODE ANN. §§ 19.340.030, 19.340.010, 19.340.100 (West 2016)

<b>Wisconsin</b>	WIS. STAT. § 632.865 (2015)
<b>Wyoming</b>	WYO. STAT. ANN. §§ 26-52-101–26-52-104 (West 2016)